A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment - Trial NCT06088043
Access comprehensive clinical trial information for NCT06088043 through Pure Global AI's free database. This Phase 3 trial is sponsored by Takeda and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Takeda
Timeline & Enrollment
Phase 3
Nov 06, 2023
Apr 15, 2026
Primary Outcome
Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) with a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo,Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI-75 Response) at Week 16 Comparing TAK-279 Against Placebo
Summary
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to
 placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be
 assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a
 placebo). Participants will be in the study for up to 56 weeks.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06088043
Non-Device Trial